Jeff Yass’s Faeth Therapeutics FTH Stock Holding History

Jeff Yass’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,903	Closed	-$18.6K	–	13388
2024 Q4	$18.6K	Sell	1,903 -2,618	-58%	-$26.3K	﹤0.01%	11925
2024 Q3	$54.1K	Buy	+4,521	New	+$55.2K	﹤0.01%	11351

Other funds holding FTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Jeff Yass's FTH Position: Q1 2025 in Review

Jeff Yass sold out of Faeth Therapeutics (FTH) in Q1 2025, closing a stake of 1,903 shares — an estimated $18.6K sold.

Jeff Yass first reported a position in FTH in Q3 2024 and held it in 2 quarters. The position peaked at $54.1K in Q3 2024. 20 funds tracked by Wall St. Rank hold FTH as of Q1 2025.

Jeff Yass reported no remaining Faeth Therapeutics position as of Q1 2025 after selling out during the quarter.
Jeff Yass sold 1,903 Faeth Therapeutics shares in Q1 2025, an estimated $18.6K.
Jeff Yass first reported a position in Faeth Therapeutics in Q3 2024 and held it in 2 quarters.
Jeff Yass's Faeth Therapeutics position peaked at $54.1K in Q3 2024.
20 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.